Pilot Projects and Trans-Network Activities Core

项目摘要/摘要：试点项目和跨网络活动核心 试点项目和跨网络活动核心的目标是支持研究的发展 使用PDX模型的项目将推进PDTC和PDXNet的使命。核心将有助于促进 使用描述人类疾病的特征良好的PDX模型进行协作、转化性研究。 项目将扩大翻译研究的范围，并增加致力于 使用PDX模型测试CTEP药物，以开发I/II期临床所需的临床前合理性 审判。申请(RFA)两个奖项，每年50,000美元将被征集。中的一个 PDTC和对非PDXNet成员开放的一个。这些项目的目标将是支持 PDTC的翻译目标是通过使用PDX模型或研究来推进翻译研究 增强跨PDTC的实验验证和重复性的方法。申请申请 基于PDX的项目将每年申请(RFA)。所有发展研究项目申请将 由科学家组成的试点研究计划咨询委员会(代表基础和 应用科学])对实体肿瘤癌症有专门知识的，生物统计学家，患者权益倡导者 成员，视需要(专门知识，无利益冲突)。这个委员会将提出建议 向PDTC领导委员会提交，该委员会将做出最终的资金决定。 相关性 拟议的工作将导致PDX作为人类疾病模型的更多使用，可用作 根据生物标志物在患者亚群中测试CTEP药物的临床前合理性。

Project Summary/Abstract: Pilot Projects and Trans-Network Activities Core The goal of the Pilot Projects and Trans-Network Activities Core is to support the development of research projects using PDX models that will advance the mission of the PDTC and PDXNet. The core will help to foster collaborative, translational research using well-characterized PDX models that recapitulate human disease. Projects will expand the scope of translational research and increase the number of investigators committed to testing CTEP agents using PDX models for developing the preclinical justification needed for Phase I/II clinical trials. Requests for Application (RFA) for two awards of $50,000 dollars a year will be solicited. One within the PDTC and one that is open to non-PDXNet members. The goal of these projects will be to support the translational goals of the PDTC to advance translational research through the use of PDX models or, research methods to enhance experimental validation and reproducibility across PDTCs. Requests for Applications (RFA) for PDX based projects will be requested annually. All developmental research project applications will be reviewed by Pilot Research Program Advisory Committee consisting of scientists (representing basic and applied science) with expertise in solid tumor cancers, a biostatistician, a patient advocate, and ad hoc members, as necessary (special expertise, no conflict of interest). This committee will make recommendations to the PDTC Leadership Committee, which will make final funding decisions. Relevance The work proposed will lead to increased utilization of PDXs as models of human disease that can be used as the preclinical justification for testing CTEP agents in patient sub-populations based on biomarkers.